What we do

Your modularised & configurable condition agnostic platform that builds world class unified health data assets, empowering patients & clinicians.

Features
  • 298% faster patient recruitment than UK average
  • Average 69% daily patient engagement in research projects
  • Unifying health data seamlessly at scale.
Applications
  • Real World Evidence projects
  • Next Generation Patient Registry Development
  • Academic Trial Recruitment
  • Pharma Launch and Re-Launch Projects
  • A Single lens across various health systems.

Trusted by leading organisations

Society for Endocrinology
Royal Brompton & Harefield NHS FT
Novo Nordisk
UKHSA
Imperial College London
BMS
University of Oxford
Optum
Society for Endocrinology
Royal Brompton & Harefield NHS FT
Novo Nordisk
UKHSA
Imperial College London
BMS
University of Oxford
Optum
40,000+
Active users across current projects
70+
Hospital sites across the UK & Ireland
298%
Faster patient recruitment in primary care-led projects
Clinical-grade real-world evidence

The data infrastructure that determines whether a launch succeeds.

Two in three drug launches miss their Year 1 forecasts, not because of the molecule, but because commercial, medical, and market access teams are making irreversible decisions about patient populations they cannot fully see. PeopleWith changes that.

Diagram showing escalating data valuation, EMA and FDA regulatory frameworks incorporating PGHD, PED and RWE, with expanding evidence range post-approval far beyond Phase I–III clinical trial populations.
Escalating data valuation. EMA & FDA regulatory frameworks now incorporate PGHD, PED & RWE, expanding the evidence range far beyond the patient profiles defined in clinical trials.
Impacting Life Sciences Globally

Clinical-grade data assets. Built before approval.

Clinical trials define who was studied. PeopleWith reveals who is actually living with the condition, capturing the true spectrum of age, co-morbidities, lifestyle, treatment compliance, and condition severity that regulators, HTA bodies, and prescribers require post-approval.

Reimbursement evidence
Arrive at HTA with prospectively collected real-world burden evidence, not inferred from trial populations that don't reflect real patient diversity.
Patient stratification
Identify which patients carry the highest unmet need at individual level, capturing differing age groups, co-morbidities, medications, symptoms, and lifestyle variances.
Treatment pathways
See exactly where patients are delayed, misdiagnosed, or stuck, and design launch strategy around the real-world pathway, not the idealised one.
Pharmacovigilance
Post-marketing safety infrastructure operational at approval, capturing adverse events with a completeness that spontaneous reporting cannot approach.
"
The difference between launch success and failure is not the molecule, and it is not the clinical trial data.
It is the evidence infrastructure built around it. Before launch. And during it. PeopleWith builds that infrastructure.